ReviewBiomedicines2023
Updates on Lymphovascular Invasion in Breast Cancer.
Review in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 51 citations in OpenAlex.
- De-Escalation of Neoadjuvant Treatment for HER2-Positive Breast Cancer.International journal of cancer · 2026Review
- A Habitat Imaging-Based Radiomics and Deep Learning Fusion for Preoperative Prediction of Lymphovascular Invasion in Invasive Breast Cancer: A Multicenter Study.Balkan medical journal · 2026Article
- Lymphovascular Invasion in SOUND-Eligible Breast Cancer: Implications for Occult Axillary Nodal Metastasis.Annals of surgical oncology · 2026Article
- Predictors of Sentinel Lymph Node Metastasis and External Validation of the MSKCC Nomogram in Breast Cancer: A Retrospective Single-Center Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Intratumoral and peritumoral-based radiomics for assessment of lymphovascular invasion in invasive breast cancer: model development and validation.Translational cancer research · 2026Article
- Artificial Intelligence and Digital Pathology for Preoperative Lymphovascular Invasion and Metastatic Risk Prediction in Breast Cancer: Bridging the Biopsy-Resection Gap.Journal of clinical medicine · 2026Review
- Keratin 6A Overexpression in the Lymphovascular Invasion-Associated Tumor Subgroup Promotes Progression of Triple-Negative Breast Cancer.Cancer research and treatment · 2026Article
- Review
- Use of contrast-enhanced mammography for preoperative prediction of lymphovascular invasion status in invasive breast cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- EVG-Based Periarterial/Perivenous Invasion (periA/V) as a High-Sensitivity Surrogate Marker for Lymph Node Metastasis in pT1 Invasive Breast Carcinoma of No Special Type.Diseases (Basel, Switzerland) · 2026Article
- Leveraging immune and clinicopathological profiles with machine learning to predict axillary lymph node metastasis in breast cancer patients.Breast cancer research : BCR · 2026Observational
- Magnetic resonance imaging-based radiomics analysis: predicting vascular invasion in breast invasive ductal carcinoma using different machine learning models.Translational cancer research · 2026Article
- Enhanced CT-Based Delta-Radiomics: Predicting Lymphovascular and Perineural Invasion in Rectal Cancer Preoperatively.Journal of imaging informatics in medicine · 2026Article
- Mapping the Intratumoral and Peritumoral Microenvironment: Multilayered Shell ADC Analysis and Its Association with Multiparametric Biomarkers in Invasive Breast Cancer.Tomography (Ann Arbor, Mich.) · 2026Article
- The effect of resiquimod (a Toll-like receptor-7/8 agonist) on the balance between pro-inflammatory and anti-inflammatory cytokines in breast cancer patients.Discover oncology · 2026Article
- Prognostic Significance of Lymphovascular Invasion in Breast Cancer: Insights From a Retrospective Analysis at a Tertiary Care Center.Saudi medical journal · 2026Article
- Refined risk stratification in residual triple-negative breast cancer after neoadjuvant therapy using residual cancer burden class and lymphovascular invasion.Breast cancer research and treatment · 2026Article
- Immunohistochemical expression of CANT1 and B3GNT3 in invasive ductal carcinoma of the breast: diagnostic and prognostic significance in lymph node metastasis.Diagnostic pathology · 2026Article
- The LVI Component Hypothesis: the lymphatic-to-vascular invasion ratio as an enrichment biomarker for therapy with PD-L1×VEGF-A bispecific antibodies.Frontiers in immunology · 2026Article
- Development and External Validation of a Preoperative Nomogram for Predicting Axillary Lymph Node Metastasis in Breast Cancer Using Routine Ultrasound and Core Needle Biopsy Variables.Cancer management and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditionally, lymphovascular invasion (LVI) has represented one of the foremost pathological features of malignancy and has been associated with a worse prognosis in different cancers, including breast carcinoma. According to the most updated reporting protocols, the assessment of LVI is required in the pathology report of breast cancer surgical specimens. Importantly, strict histological criteria should be followed for LVI assessment, which nevertheless is encumbered by inconsistency in interpretation among pathologists, leading to significant interobserver variability and scarce reproducibility. Current guidelines for breast cancer indicate biological factors as the main determinants of oncological and radiation therapy, together with TNM staging and age. In clinical practice, the widespread use of genomic assays as a decision-making tool for hormone receptor-positive, HER2-negative breast cancer and the subsequent availability of a reliable prognostic predictor have likely scaled back interest in LVI's predictive value. However, in selected cases, the presence of LVI impacts adjuvant therapy. This review summarizes current knowledge on LVI in breast cancer with regard to definition, histopathological assessment, its biological understanding, clinicopathological association, and therapeutic implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.